New Delhi: Drug agency Glenmark Prescribed drugs on Monday mentioned it has discount of its antiviral drug Favipiravir, beneath the model title FabiFlu, for the therapy of sufferers with delicate to reasonable COVID-19, by 27 per cent to Rs 75 per pill.
Glenmark Prescribed drugs had launched FabiFlu final month at a value of Rs 103 per pill.
In a regulatory submitting Glenmark introduced a value discount of 27 per cent for FabiFlu. The brand new most retail value (MRP) is Rs 75 per tab, it mentioned.
“The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country,” the submitting mentioned.
“Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country,” Glenmark Prescribed drugs Senior Vice President and Head India enterprise Alok Malik mentioned.
Additional, the corporate has commenced a publish advertising and marketing surveillance (PMS) examine on FabiFlu to carefully monitor the efficacy and security of the drug in 1,00zero sufferers which are prescribed with the oral antiviral, as a part of an open label, multicenter, single arm examine, the submitting added.
“We expect this post marketing surveillance study to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu,” Malik added.
On June 20, Glenmark introduced that it obtained manufacturing and advertising and marketing approval from India’s drug regulator for FabiFlu, making it the primary oral Favipiravir-approved remedy in India for the therapy of delicate to reasonable COVID-19.
Glenmark has additionally accomplished the part three medical trial with Favipiravir (FabiFlu) in delicate to reasonable COVID-19 sufferers in India. The trial outcomes might be out there shortly, the corporate mentioned.
Glenmark can be conducting one other part three medical trial to guage the efficacy of two antivirals medication Favipiravir and Umifenovir as a mix remedy in reasonable hospitalised grownup COVID-19 sufferers in India.
Shares of Glenmark Pharma have been buying and selling 1.34 per cent decrease at Rs 421.00 apiece on BSE.
IIIT Delhi Develops AI Mannequin To Repurpose Present Medication To Deal with COVID19
Ldl cholesterol-Reducing Medication Might Drop COVID Sufferers’ Fatality Price